Last reviewed · How we verify
NCT01081028
Connect® MM- The Multiple Myeloma Disease Registry
Terminated
Last updated 13 April 2026
What this trial tests
trial testing First-line therapy in Multiple Myeloma in 3,011 participants. Terminated before completion.
Timeline
1 September 2009
Primary endpoint
31 December 2024
31 December 2024
31 December 2024
Quick facts
| Lead sponsor | Celgene |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 3,011 |
| Start date | 1 September 2009 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 253 locations across Puerto Rico, United States |
Drugs / interventions tested
- First-line therapy
- Second-line Multiple Myeloma treatments — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Celgene — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
Jagannath S, Lin Y, Goldschmidt H, Reece D, et al · · 2021 · cited 69× · PMID 34145225 · DOI 10.1038/s41408-021-00507-2 -
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Abonour R, Wagner L, Durie BGM, Jagannath S, et al · · 2018 · cited 36× · PMID 30056582 · DOI 10.1007/s00277-018-3446-y -
Recognition of early mortality in multiple myeloma by a prediction matrix.
Terebelo H, Terebelo H, Srinivasan S, Narang M, et al · · 2017 · cited 34× · PMID 28543165 · DOI 10.1002/ajh.24796 -
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.
Ailawadhi S, Jagannath S, Lee HC, Narang M, et al · · 2020 · cited 25× · PMID 32706404 · DOI 10.1002/cncr.33089 -
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Costello C, Davies FE, Cook G, Vela-Ojeda J, et al · · 2019 · cited 24× · PMID 30816809 · DOI 10.2217/fon-2019-0013 -
Connect MM Registry as a national reference for United States multiple myeloma patients.
Ailawadhi S, Jagannath S, Narang M, Rifkin RM, et al · · 2020 · cited 17× · PMID 31701679 · DOI 10.1002/cam4.2656 -
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect<sup>®</sup> MM Registry.
Lee HC, Ailawadhi S, Gasparetto CJ, Jagannath S, et al · · 2021 · cited 15× · PMID 34301916 · DOI 10.1038/s41408-021-00524-1 -
Development of a prognostic model for overall survival in multiple myeloma using the Connect<sup>®</sup> MM Patient Registry.
Terebelo HR, Terebelo HR, Abonour R, Gasparetto CJ, et al · · 2019 · cited 14× · PMID 31382320 · DOI 10.1111/bjh.16139
Verify or expand the search:
- PubMed search for NCT01081028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Celgene trials
Trials by the same sponsor.
- NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
- NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
- NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
- NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
- NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT01081028 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Celgene
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01081028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing